Advancing Patient-Centered Outcomes and Equity in Clinical Trials for BCG-Unresponsive Nonmuscle Invasive Bladder Cancer
Authors:
- 1 November 2023
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 9 (11) , 1491-1492
Abstract
This Viewpoint encourages investigators to move beyond FDA guidance toward patient-centered therapies and health equity for BCG-unresponsive bladder cancer.Keywords
This publication has 5 references indexed in Scilit:
- New Federal Incentives for Diversity in Clinical TrialsNew England Journal of Medicine, 2022
- International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder CancerEuropean Urology, 2022
- Efficacy, Safety, and Regulatory Approval of Food and Drug Administration–Designated Breakthrough and Nonbreakthrough Cancer MedicinesJournal of Clinical Oncology, 2018
- Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer GroupJournal of Clinical Oncology, 2016
- Clinical Trial Design for the Development of New Therapies for Nonmuscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public WorkshopUrology, 2014